Telix Pharmaceuticals (OTCMKTS:TLPPF) Trading Down 4.3% – Should You Sell?

Telix Pharmaceuticals Limited (OTCMKTS:TLPPF) was down 4.3% during trading on Wednesday . The company traded as low as $14.75 and last traded at $14.75. Approximately 820 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 7,026 shares. The stock had previously closed at $15.41.

Telix Pharmaceuticals Price Performance

The business has a 50-day simple moving average of $14.27 and a 200 day simple moving average of $12.83.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its products portfolio include Illuccix for the treatment of prostate cancer;, TLX591, a radio antibody-drug conjugate, which is in phase 3 clinical trial for the treatment of prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma.